257 results about "Receptor modulator" patented technology

Disclosed is a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of:a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof; anda pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15.Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.

The disclosure provides methods the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis, and for protecting or reinforcing the blood-brain barrier, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A.

The present invention relates to pyridinyl derivatives of Formula (I) Formula (I) wherein R1, R2, R3, R4, R5, R6, Ar1, L, W, Z, m and n are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as LPA1 receptor modulators.

The present invention relates to compounds of formula (I), their synthesis and their use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders. [Formula 1] TIFF2023523300000191.tif51156

Compounds, pharmaceutical compositions, kits, and methods for treating an inflammatory disease, disorder, or condition. The method includes administering to a patient in need thereof: an effective amount of a compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, or a metabolite thereof, and an effective amount of a S1P receptor modulator or a pharmaceutically acceptable salt thereof, to treat the inflammatory disease, disorder, or condition. The compound of formula (I) has the following formula:

Hallucinogenic and non-hallucinogenic serotonin receptor agonists are disclosed herein in addition to methods of using them for treating and preventing addictions and overdoses.

The present disclosure relates to compounds useful as proton activated G protein coupled receptor modulators and pharmaceutical compositions comprising the compounds. The present disclosure also relates to methods of using such compounds and pharmaceutical compositions to treat and / or prevent diseases, disorders or conditions mediated by proton activated G protein coupled receptors.

There are disclosed certain 3-azabicyclo[3.1.0]hexanes, and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are GLP-1 receptor modulators and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions, for example Type 2 diabetes.

Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and / or diagnosis.

Disclosed herein are salts and solid forms of the benzoselenophene and benzothiophene analogs described herein.

The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory / autoimmune diseases / disorders and cancer.

The present disclosure provides conjugates comprising at least one psychedelic compound or a precursor thereof and at least one N-methyl D-aspartate (NMD A) receptor (NMD AR) modulator or a precursor thereof, compositions comprising the same and uses thereof.

The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.

The present disclosure relates to a compound of formula (I), a stereoisomer, isotopically labeled compound, hydrate, solvate, or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and a use thereof in the treatment of CXCR7-mediated diseases.

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

The present invention relates to novel 5HT receptor modulators, such as compounds of general formula (I) and general formula (II) or pharmaceutically acceptable salts thereof. Methods of using the compounds include, for example, modulation of serotonin (5-HT) receptor subtypes, including the serotonin 2A receptor and / or serotonin 2C receptor, and treatment of conditions or diseases wherein the treatment is associated with modulation of serotonin 2A receptor and / or serotonin 2C receptor. # imgabs 0 # formula (I) # imgabs 1 # formula (II).

The present disclosure provides, inter alia, Compounds of Formula (I)or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

A compound for use in the treatment of itch is provided, wherein the compound comprises the general formula (1a), general formula (1b) or general formula (1c). The compounds of the invention are positive allosteric α2 and / or α3 GABAA receptor modulators.

The invention discloses an orexin receptor modulator as well as a preparation method and application thereof, and particularly discloses an orexin receptor antagonist shown in the following formula. The orexin receptor antagonist provided by the invention can be used for treating nervous system related diseases. # imgabs0 #

In one aspect, the present application provides azabicyclo and diazepine derivatives useful as muscarinic receptor modulators. In another aspect, the present application provides pharmaceutical compositions for the treatment of ocular diseases, the compositions comprising at least one muscarinic receptor modulator. Formulas (I) and (II):

Abstract GPCR Receptor Agonists, Pharmaceutical Compositions Containing Them, and Methods of Use Thereof The application provides GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of administration thereof, and methods of use thereof for treatment and / or diagnosis. 010-9319-5532 / 1 / AMERICAS 010-9319-5532 / 1 / AMERICAS 48513847.1 1

Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and / or diagnosis.

The present invention features methods for reducing alcohol intake, intake of drugs of abuse, food intake, or to increase fat breakdown or lipolysis by administering a sphingosine-1-phosphate receptor modulator.

The present invention relates to an insecticidal and acaricidal composition. The composition contains active component A and active component B, wherein the active component A is selected from compound I; the active component B is selected from one or more of bionic juvenile hormones, chitin biosynthesis inhibitors affecting CHS1, type-1 chitin biosynthesis inhibitors, ecdysone receptor agonists, nicotinic acetylcholine receptor competitive modulators, ryanodine receptor modulators, nicotinic acetylcholine receptor allosteric modulators, glutamate-gated chloride channel allosteric modulators, sodium channel modulators, voltage-dependent sodium channel blockers, inhibitors, trifluoroethyl sulfide acaricides, other insecticides and acaricides, etc.; and the active component A has a structure as follows. The composition of the present invention has advantages such as obvious synergistic effects and delayed resistance development, and can be used for controlling a variety of pests.

Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof, wherein R is as defined herein. Such compounds serve as modulators of the sphingosine-1-phosphate receptor, and have utility for treatment of a malcondition for which activation of this receptor is medically indicated.

Disclosed in the present invention are an orexin receptor modulator, and a preparation method therefor and the use thereof, and specifically disclosed is an orexin receptor antagonist as shown in the following formula. The orexin receptor antagonist provided by the present invention can be used for treating diseases related to the nervous system.

The present disclosure provides azocino[4,5,6-cd]indoles as serotonin receptor modulators. Uses of said compounds in the treatment of medical disorders, such as neurological or psychiatric disorders, and processes of synthesizing said compounds are also provided.

Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and / or diagnosis.